The effect of curcumin on paraproteinemia and bone turnover in patients with monoclonal gammopathy of undefined significance (MGUS) and indolent myeloma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000962033

Acronym

nil

Enrollment

Registered

2010-11-09

Start date

2010-01-27

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Due to the results of previous studies both in vivo and in vitro, we hypothesised that curcumin may decrease paraproteinemia and bone turnover in MGUS and indolent myeloma patients. A pilot study conducted by us showed a reduction in paraprotein levels and the uNTX bone turnover marker in a select group of MGUS patients. This trial is a continuation of the pilot study and we aim to prove that curcumin may act to prevent the progression of MGUS to active myeloma.

Interventions

curcumin - complementary medicine. patients will be administered either 4g curcumin or 4g placebo per day at the start of the study. After 3 months they will be crossed over for a futher 3 months. There is no wash-out period. The curcumin is being administered as stick-packs of granules.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

40 Years to 90 Years

Healthy volunteers

Inclusion criteria

significant paraproteinemia as defined by a serum M-protein value of equal to or greater than 18g/L.

Exclusion criteria

other malignancies

Outcome results